Skip to content

The effect of oral omega3 on exposure keratopathy

The effect of oral omega3 on exposure keratopathy in patients admitted to the intensive care unit

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180107038251N7
Enrollment
51
Registered
2023-02-20
Start date
2023-04-21
Completion date
Unknown
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exposure keratopathy. Disorders of sclera, cornea, iris and ciliary body

Interventions

Intervention 1: Intervention group: Wash hands before eye care, Check daily eyes with fluorescein paper and cobalt filter flashlights, If eyes are closed, two tear drops will be used every four hours

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients over 18 years of old and under 65 years of old Unconscious patients with GCS score less than 10 without blinking reaction No obvious damage to the face and eyes No dry eyes before admission Do not use eye drops before admission Having a stomach tube and enteral nutrition based on medical prescription Having no keratopathy at the start of the study

Exclusion criteria

Exclusion criteria: discharge or transport from ICU death Return of corneal refraction and increased consciousness (GCS score 10 and above) Not receiving food by mouth based on the doctor's diagnosis Creating scratches and damage from instruments or other medical errors Active allergy or infection on surface of eye Treatment with topical steroidal or non-steroidal ophthalmic anti-inflammatory drugs History of using anti-anxiety, anti-depressant, anti-hypertensive and antihistamine drugs History of surgery in last 3 months Head and neck radiotherapy Use of omega-3 supplements in last 3 months History of allergy to fish oil

Design outcomes

Primary

MeasureTime frame
Exposure keratopathy severity. Timepoint: Before the study, every morning to 1 week. Method of measurement: Examination with fluorescein paper and flashlight with cobalt blue light filter.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArak University of Medical Sciences

Arak University of Medical Sciences

nazaninamini69@yahoo.com+98 86 3417 3507

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026